Massivemarkets

Nasdaq: VOGX · Listed Aug 12, 2026

Vogenx IPO

IPO price

$13.00

Vogenx (VOGX) priced its IPO at $13.00 a share and has traded on Nasdaq since Aug 12, 2026.

VOGX today$12.34-5.08%since IPO15-min delayed · as of 7:30:02 PM EST on Nov 18, 2026

See the VOGX quote

First trading day · Aug 12, 2026

VWAP 13.02first trade 13.00high 13.15$13.04volume · rising bars above the line, falling bars below17.31K12:104:00
IPO price
$13.00
the top of the range of $11 to $13
First trade
$13.00
+0.00% from the IPO price
First-day last trade
$13.04
+0.31% from the IPO price, regular session
Raise
$81.25M
before the underwriters' option

These numbers are from the first trading day, Aug 12, 2026.

How VOGX did against the market

VOGX against the market, from its first trade at 12:10 ET to the last trade of the session.

VOGX from its first trade
+0.31%
Against the market (QQQ)
+0.4 pts

VOGX rose 0.3% from its first trade to the last trade of the session. That is 0.4 points better than the market.

Same-day moves do not show that VOGX caused them. The market is QQQ, the Nasdaq-100 ETF.

The debut race

VOGX against other big listings, as the percent change from each stock's own IPO price.

The first 30 trading days. Each point is the last regular-session trade of a day.

+50%+100%+150%+200%+250%IPOday 1day 5day 10day 15day 20day 25day 30Figma '25 +69.64%Reddit '24 +40.32%CoreWeave '25 +28.42%Arm '23 -3.06%Klarna '25 -7.33%VOGX +100.00%

The IPO scoreboard

VOGX against 6 other big listings: the return from each IPO's own price at the first trade, the close of day 1, day 5, and day 30.

VOGX against other big IPOs: the money raised, and the return from each IPO price at the first trade, at the last trade of day 1, and on day 5 and day 30.
IPORaisedFirst tradeDay 1 closeDay 1 close, as a barDay 5Day 30
Vogenx '26$81.25M+0.00%+0.31%+50.08%+100.00%
Figma '25$1.22B+157.58%+252.42%+173.64%+69.64%
Circle '25$1.05B+122.58%+168.45%+278.18%+622.98%
Reddit '24$748M+38.24%+47.97%+69.90%+40.32%
Arm '23$5.23B+10.00%+23.76%+3.63%-3.06%
Klarna '25$1.37B+30.00%+16.14%+13.73%-7.33%
CoreWeave '25$1.5B-2.50%+0.02%+34.32%+28.42%

Day 1 is the last regular-session trade of the first day. Day 5 and day 30 are the last trade of the fifth and thirtieth trading day, counting the listing day as day 1. A cell fills in when that day has traded.

The offering

The Vogenx IPO offers 6.25M shares to raise $81.25M, before any underwriters' option.

$9$11$12$13$15
Expected price range
$11 to $13
IPO price
$13.00
Shares offered
6.25M
Money raised
$81.25M
Listing date
Aug 12, 2026
Exchange
Nasdaq
Security
Ordinary Shares

Money raised, against the largest IPOs

  • Alibaba '14$21.77B
  • Facebook '12$18.41B
  • Rivian '21$11.93B
  • Uber '19$8.1B
  • Arm '23$5.23B
  • Vogenx$81.25M

Where VOGX ranks

Vogenx's market cap against the largest US-listed companies.

Market cap, against the largest US-listed companies

  • AAPL$5.12T
  • MSFT$3.77T
  • NVDA$3.65T
  • GOOGL$3.47T
  • AMZN$2.9T
  • TSM$1.88T
  • AVGO$1.69T
  • META$1.58T
  • TSLA$1.52T
  • BRK.B$1.22T
  • VOGX$183.31M

Filings and the company

What Vogenx has disclosed to the SEC, and the basic facts about the listing.

8-K filings

Material events that Vogenx discloses to the SEC on Form 8-K.

  • On November 6, 2026, Vogenx, Inc. issued a press release announcing its financial results for the fiscal quarter ended September 30, 2026.

  • Director departureOct 9, 2026

    On October 7, 2026, concurrent with his becoming an employee of Vogenx, Inc. (the "Company") as Chief Commercial Officer, Richard Gorman resigned from the Board of Directors ("Board") of the Company and from all committees of the Board on which he served, including the Audit Committee, the Compensation Committee, and the Nominating and Corporate Governance Committee, effective October 12, 2026. Mr. Gorman's resignation was not the result of any disagreement with the Company on any matter relating to the Company's operations, policies or practices.

  • Director appointmentSep 22, 2026

    On September 21, 2026, the Board of Directors ("Board") of Vogenx, Inc. (the "Company") appointed Ken Toombs to the Board as a Class II director, to serve until the 2028 annual meeting of stockholders of the Company or until his successor is duly elected and qualified or until his earlier death, resignation or removal. The Board determined that Mr. Toombs qualifies as an "independent director" under the listing rules of the Nasdaq Stock Market and applicable rules and regulations of the Securities and Exchange Commission.

  • Underwriting agreementAug 19, 2026

    Under the terms of an underwriting agreement dated August 11, 2026 (the "Underwriting Agreement") by and between the Company and JonesTrading Institutional Services LLC (the "Underwriter"), the Company granted the Underwriter a 45-day option to purchase up to 937,500 additional shares of common stock at the public offering price of $13.00 (the "Over-Allotment Option").

  • Charter amendmentAug 13, 2026

    The Company filed a second amended and restated certificate of incorporation (the 'Amended and Restated Charter') with the Secretary of State of the State of Delaware. The Amended and Restated Charter amends and restates the Company's existing amended and restated certificate of incorporation, as amended, in its entirety to, among other things, (i) authorize 500,000,000 shares of common stock, par value $0.0001 per share; (ii) eliminate all references to the previously existing series of preferred stock; and (iii) authorize 10,000,000 shares of undesignated preferred stock, par value $0.0001 per share.

About Vogenx

Vogenx Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies for the treatment of serious diseases associated with dysfunctions in human metabolism, including post-bariatric hypoglycemia, or PBH, and gastroparesis. The company's flagship product candidate, mizagliflozin, is an orally administered, minimally absorbed, small molecule drug candidate being developed for the treatment of post-bariatric hypoglycemia (PBH), gastroparesis and GIP-induced Cushing's Syndrome. It operates as a single reportable segment engaged in the discovery and development of treatments for serious metabolic and gastrointestinal diseases.

Ticker
VOGX
Exchange
Nasdaq
Market
stocks
Type
CS
Currency
USD
Industry
PHARMACEUTICAL PREPARATIONS
Employees
7
Listed
Aug 12, 2026
Security
Ordinary Shares
Company website

Frequently asked questions

What was the Vogenx IPO price?

$13.00 a share.

When did Vogenx go public?

Vogenx listed on Nasdaq on Aug 12, 2026 under the ticker VOGX.

How much did the Vogenx IPO raise?

$81.25M, before any underwriters' option.

How did Vogenx open on its first day?

VOGX first traded at $13.00, +0.00% from the IPO price of $13.00.

How did VOGX close on its first day?

Its last regular-session trade was $13.04, +0.31% from the IPO price of $13.00.

What was the VOGX first-day trading range?

$12.95 to $13.88 in the regular session.

How many VOGX shares traded on the first day?

667.55K shares in the regular session.

How many shares did Vogenx sell in its IPO?

6.25M shares.

How did VOGX do against the market on its first day?

VOGX rose 0.3% from its first trade to the last trade of the session. That is 0.4 points better than the market (QQQ, the Nasdaq-100 ETF).

What exchange is VOGX listed on?

Vogenx lists on Nasdaq under the ticker VOGX.

Build with Massive

Get the VOGX data behind this page

The Massive endpoint behind each section of this page
What the page showsEndpoint
Offering terms and dates/vX/reference/ipos
Price/v3/snapshot
Chart, VWAP, and the market comparison/v2/aggs/ticker/VOGX/range/5/minute
Market cap/v3/reference/tickers/VOGX
News/v2/reference/news
Filings/vX/disclosures

Nothing on this page is investment advice. All data and content is provided for informational purposes under our Terms of Service.